Keyphrases
Murine Model
100%
Hepatocellular Carcinoma
100%
Histone Deacetylase Inhibitor (HDACi)
100%
Suberoylanilide Hydroxamic Acid
100%
Tumor Xenograft
40%
Therapeutic Strategies
20%
Cancer Cell Survival
20%
Antitumor Effect
20%
Tumor Burden
20%
Tumor Growth
20%
In Vivo Model
20%
B-cell Lymphoma
20%
Oral Administration
20%
Therapeutic Potential
20%
Multiple Aspects
20%
Antitumor Activity
20%
Cancer Causes
20%
Cancer Mortality
20%
IC50 Value
20%
In Vivo Efficacy
20%
Survivin
20%
Every Other Day
20%
Huh7 Cells
20%
Orally Bioavailable
20%
Athymic nude Mice
20%
Tumor Suppression
20%
Xenograft Tumor Model
20%
Start of Treatment
20%
Apoptosis Regulation
20%
Apoptogenic
20%
Orthotopic Xenograft
20%
Human Hepatocellular Carcinoma
20%
Oral Treatment
20%
Clinical Value
20%
Phosphorylated Akt
20%
Cellular Inhibitor of Apoptosis Protein 2
20%
Cytokine-induced Apoptosis Inhibitor 1
20%
Median Inhibitory Concentration
20%
Apoptotic Regulator
20%
Advanced Hepatocellular Carcinoma
20%
Hep3B Cells
20%
Phenylbutyrate
20%
Large Tumors
20%
Subcutaneous Xenograft
20%
Ectopic Tumor
20%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Histone Deacetylase Inhibitor
100%
Vorinostat
100%
Neoplasm
80%
Histone Deacetylase
40%
IC50
40%
Biological Marker
20%
Malignant Neoplasm
20%
Tumor Growth
20%
Nude Mouse
20%
Survivin
20%
Antitumor Activity
20%
Tumor Model
20%
B Cell Lymphoma
20%
Cancer Mortality
20%
Cancer Inhibition
20%
Arylbutyric Acid Derivative
20%
Baculoviral IAP Repeat Containing Protein 3
20%
Inhibitor of Apoptosis Protein 2
20%